Гастроэнтерологические проявления метаболического синдрома

DOI: https://doi.org/10.29296/25877305-2018-12-01
Скачать статью в PDF
Номер журнала: 
12
Год издания: 
2018

Ю. Успенский(1, 2), доктор медицинских наук, профессор, Ю. Фоминых(2), кандидат медицинских наук, доцент, Я. Соусова(1), З. Гулунов(1), Р. Ниязов(3) 1-Санкт-Петербургский государственный педиатрический медицинский университет 2-Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова 3-ФКУЗ «МСЧ МВД России по Санкт-Петербургу и Ленинградской области» E-mail: jaf@mail.ru

Одной из новых концепций метаболического синдрома стала теория существования гастроэнтерологических кластеров. Изучение взаимосвязи между метаболическим синдромом и некоторыми заболеваниями желудочно-кишечного тракта позволяет рассматривать последние в качестве диагностических критериев, однако без четкого понимания всех аспектов формирования этой корреляции невозможно использование имеющейся информации в практической медицине, что оставляет задачу нерешенной.
Ключевые слова: 
гастроэнтерология
метаболический синдром
ожирение
инсулинорезистентность
гастроэзофагеальная рефлюксная болезнь
неалкогольная жировая болезнь печени
желчнокаменная болезнь
неалкогольная жировая болезнь поджелудочной железы
Для цитирования
Успенский Ю., Фоминых Ю., Соусова Я., Гулунов З. Ниязов Р. Гастроэнтерологические проявления метаболического синдрома . Врач, 2018; (12): 3-8 https://doi.org/10.29296/25877305-2018-12-01

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

Список литературы: 
  1. World Health Organization Department of Noncommunicable Disease Surveillance. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation / Geneva, Switzerland: World Health Organization, 1999. (Publication no. WHO/NCD/NCS/99.2).
  2. Balkau B., Charles M. Commet on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistence (EGIR) // Diabet. Med. – 1999; 16: 442–3.
  3. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final Report // Circulation. – 2002; 106: 3143–421.
  4. Zachary T. Bloomgarden. American Association of Clinical Endocrinologists (AACE) Consensus Conference on the Insulin Resistance Syndrome // Diabet. Care. – 2003; 26 (3): 933–9. https://doi.org/10.2337/diacare.26.3.933
  5. Grundy S. Metabolic syndrome pandemic // Arteriosclerosis Thrombosis Vascular Biology. – 2008; 28 (4): 629–36. DOI: 10.1161/ATVBAHA.107.151092.
  6. Grundy S., Cleeman J., Daniels S. et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement // Circulation. – 2005; 112: 2735–52.
  7. Goodman E., Daniels S., Meigs J. et al. Instability in the diagnosis of metabolic syndrome in adolescents // Circulation. – 2007; 115: 2316–22.
  8. Weiss R., Bremer A., Lustig R. What is metabolic syndrome, and why are children getting it? // Ann. NY Acad. Sci. – 2013; 1281: 123–40. DOI: 10.1111/nyas.12030.
  9. Agudelo G., Bedoya G., Estrada A. et al. Variations in the prevalence of metabolic syndrome in adolescents according to different criteria used for diagnosis: which definition should be chosen for this age group? // Metab. Syndr. Relat. Disord. – 2014; 12: 202–9. DOI: 10.1089/met.2013.0127
  10. Ford E., Li C. Defining the metabolic syndrome in children and adolescents: will the real definition please stand up? // J. Pediatr. – 2008; 152: 160–4. DOI: 10.1016/j.jpeds.2007.07.056.
  11. Zimmet P., Alberti G., Kaufman F. et al. International Diabetes Federation Task Force on Epidemiology and Prevention of Diabetes The metabolic syndrome in children and adolescents // Lancet. – 2007; 369: 2059–61. DOI: 10.1016/S0140-6736(07)60958-1.
  12. Успенский Ю.П., Балукова Е.В., Барышникова Н.В. Гастроэзофагеальная рефлюксная болезнь у больных с ожирением // Поликлиника. – 2015; 1–1: 14–6.
  13. Фадеенко Г.Д., Гриднев А.Е. Гастроэзофагеальная рефлюксная болезнь: пищеводные, внепищеводные проявления и коморбидность / Киев, «Здоровье Украины», 2014; 376 с.
  14. Dent J., Ei-Serag H., Wallander M. Epidemiology of gastro-esophageal reflux disease: a systematic review // Gut. – 2005; 54: 710–7.
  15. Dent J., Brun J., Fendric A. et al. An evidence-based appraisal of reflux disease management – the Genval Workshop Report // Gut. – 1999; 44 (suppl. 2): S1–S16.
  16. Титгат Г. Патогенез ГЭРБ // Эксперим. и клин. гастроэнтерол. Спец. вып. – 2004; 5: 6–11.
  17. Лазебник Л.Б., Машарова А.А., Бородин Д.С. Результаты многоцентрового исследования «Эпидемиология гастроэзофагеальной рефлюксной болезни в России» (МЭГРЭ) // Тер. арх. – 2011; 1: 5–25.
  18. Emerenziani S., Woald J. Gastro-esophageal reflux disease and obesity, where is the linc? // Gastroenterology. – 2013; 19 (39): 6536–9.
  19. Singh S., Lee J., Gupta N. Weight loss can lead to resolution of gastroesophageal reflux disease symptoms: a prospective intervention trial // Obesity. – 2013; 21: 284–90.
  20. Catanzaro R., Calabrese F., Occhipinti S. et al. Nonalcoholic Fatty Liver Disease Increases Risk for Gastroesophageal Reflux Symptoms // Dig. Dis. Sci. – 2014; 59 (8): 1939–45. DOI: 10.1007/s10620-014-3113-7
  21. Пасиешвили Л.М., Железнякова Н.М., Пасиешвили Т.М. Генетические детерминанты сердечно-сосудистого риска у больных с гастроэзофагеальной рефлюксной болезнью и ожирением // Эксперим. и клин. гастроэнтерол. – 2017; 142 (6): 40–3.
  22. Bedogni G., Miglioli L., Masutti F. et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study // Hepatology. – 2005; 42: 44–52.
  23. Ивашкин В.Т., Драпкина О.М., Шульпекова Ю.О. Диагностика и лечение неалкогольной жировой болезни печени (методические рекомендации) / М.: ООО «Издательский дом «М-Вести», 2009; 20 с.
  24. Ивашкин В.Т., Драпкина О.М., Маев И.В. и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования ДИРЕГ-2 // РЖГГК. – 2015; 6: 31–41.
  25. Day C., James O. Steatohepatitis: a tale of two «hits»? // Gastroenterology. – 1998; 114: 842–5.
  26. Bellentani S., Saccoccio G., Masutti F. et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy // Ann. Intern. Med. – 2000; 132: 112–7.
  27. Angulo P. Nonalcoholic fatty liver disease // N. Engl. J. Med. – 2002; 346: 1221–31.
  28. Marchesini G., Marzocchi R. Metabolic syndrome and NASH // Clin. Liver Dis. – 2007; 11: 105–17.
  29. Donati G., Stagni B., Piscaglia F. et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance// Gut. – 2004; 53: 1020–3.
  30. Ruhl C., Everhart J. Gallstone Disease is Associated with Increased Mortality in the United States // Gastroenterology. – 2011; 140 (2): 508–16. DOI: 10.1053/j.gastro.2010.10.060.
  31. Freeman J., Boomer L., Fursevich D. et al. Ethnicity and insurance status affect health disparities in patients with gallstone disease // J. Surg. Res. – 2012; 175, 1–5. https://doi.org/10.1016/j.jss.2011.06.064.
  32. Van Erpecum K. Pathogenesis of cholesterol and pigment gallstones: an update // Clin. Res. Hepatol. Gastroenterol. – 2011; 35 (4): 281–7.
  33. Biddinger S., Haas J., Yu B. et al. Hepatic insulin resistance directly promotes formation of cholesterol gallstones // Nature Medicine. – 2008; 14 (7): 778–82.
  34. Marschall H., Einarsson C. Gallstone disease // J. Internal. Med. – 2007; 261 (6): 529–42.
  35. Twisk J., Hoekman M., Lehmann E. et al. Insulin suppresses bile acid synthesis in cultured rat hepatocytes by down-regulation of cholesterol 7 a-hydroxylase and sterol 27-hydroxylase gene transcription // Hepatology. – 1995; 21 (2): 501–10.
  36. Adiels M., Olofsson S., Taskinen M. et al. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome // Arteriosclerosis Thrombosis Vascular Biology. – 2008; 28 (7): 1225–36.
  37. Acalovschi M., Blendea D., Feier C. et al. Risk factors for symptomatic gallstones in patients with liver cirrhosis: a case–control study // Am. J. Gastroenterol. – 2003; 98 (8): 1856–60.
  38. Nakeeb A., Comuzzie A., Al Azzawi H. et al. Insulin resistance causes human gallbladder dysmotility // J. Gastrointestinal Surg. – 2006; 10 (7): 940–8.
  39. Lin Y., Chen Y., Hu N. et al. The association of age, gender and metabolic factors with gallstone disease // Gastroenterological Journal of Taiwan. – 2011; 28: 11–8.
  40. Chen L.-Y., Qiao Q.-H., Zhang S.-C. et al. Metabolic syndrome and gallstone disease // World J. Gastroenterol. – 2012; 18 (31): 4215–20. DOI: 10.3748/wjg.v18.i31.4215.
  41. Housset C. Gallstone disease, towards a better understanding and clinical practice // Curr. Opin. Gastroenterol. – 2018; 34 (Issue 2): 57–8 DOI: 10.1097/MOG.0000000000000425.
  42. Pattinson N., Willis K., Frampton C. Comparative analysis of cholesterol transport in bile from patients with and without cholesterol gallstones // J. Lipid Res. – 1991; 32: 205–14.
  43. Zhang D., Xiang J., Wang L. et al. Comparative Proteomic Analysis of Gallbladder Bile Proteins Related to Cholesterol Gallstones // PLoS One. – 2013; 8 (1): e54489. https://doi.org/10.1371/journal.pone.0054489.
  44. Weerakoon H., Ranasinghe S., Navaratne A. et al. Serum lipid concentrations in patients with cholesterol and pigment gallstones // BMC Research Notes. – 2014; 7: 548. DOI: 10.1186/1756-0500-7-548.
  45. Upala S., Sanguankeo A., Jaruvongvanich V. Gallstone Disease and the Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Observational Studies // Scand. J. Surg. – 2016; 106 (Issue 1): 21–7.
  46. GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015 // Lancet. – 2016; 388 (10053): 1659–724.
  47. Abhishek M., Nicolas J., Henry A. et al. Pancreatic Steatosis Promotes Dissemination and Lethality of Pancreatic Cancer. South Surgical Association 120th Annual Meeting, West Palm Beach, Florida. December 2008. Published online: March 26, 2009. American College of Surgeons. DOI: https://doi.org/10.1016/j.jamcollsurg.2008.12.06
  48. Cosmas R., Rino A. Non-alcoholic fatty pancreas disease as a risk factor for pancreatic cancer based on endoscopic ultrasound examination among pancreatic cancer patients: A single-center experience / Australia: Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons, 23 December 2017. http://doi.org/10.1002/jgh3.12032
  49. Kim M., Chun H., Park J. et al. The association between ectopic fat in the pancreas and subclinical atherosclerosis in type 2 diabetes // Diabet. Res. Clin. Pract. – 2014; 106: 590–6.
  50. Acharya C., Navina S., Singh V. Role of pancreatic fat in the outcomes of pancreatitis // Pancreatology. – 2014; 14: 403–8.
  51. Della Corte C., Mosca A., Majo F. et al. Nonalcoholic fatty pancreas disease and Nonalcoholic fatty liver disease: more than ectopic fat // Clin. Endocrinol. (Oxford Academic). – 2015; 83: 656–62
  52. Smits M., van Geenen E.-J. The clinical significance of pancreatic steatosis // Nat. Rev. Gastroenterol. Hepatol. – 2011; 8 (3): 169–77.
  53. Olsen T. Lipomatosis of the pancreas in autopsy material and its relation to age and overweight // Acta Pathologica Microbiologica Scandinavica A. – 1978; 86 A (5): 367–73.
  54. Stamm B. Incidence and diagnostic significance of minor pathologic changes in the adult pancreas at autopsy: a systematic study of 112 autopsies in patients without known pancreatic disease // Human Pathology. – 1984; 15 (7): 677–83.
  55. van Geenen E.-J., Smits M., Schreuder T. et al. Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease // Pancreas. – 2010; 39 (8): 1185–90.
  56. Matsumoto S., Mori H., Miyake H. et al. Uneven fatty replacement of the pancreas: evaluation with computed tomographic // Radiology. – 1995; 194: 453–8.
  57. Pinnick K., Collins S., Londos C. et al. Pancreatic ectopic fat is characterized by adipocyte infiltration and altered lipid composition // Obesity (Silver Spring). – 2008; 16: 522–30.
  58. Feldman M., Friedman L., Brandt L. Sleisenger and Fortran’s Gastrointestinal and Liver Disease. 10th ed. / Philadelphia: Elsevier, 2016; 1428–41.
  59. Tse-Ya Yu, Chih-Yuan Wang. Impact of non-alcoholic fatty pancreas disease on glucose metabolism // J. Diabet. Investigation. – 2017; 8: 735–47. DOI: 10.1111/jdi.12665
  60. Wang C., Ou H., Chen M. et al. Enigmatic ectopic fat: prevalence of nonalcoholic fatty pancreas disease and its associated factors in a Chinese population // J. Am. Heart Assoc. – 2014; 3 (1): e000297.
  61. Szczepaniak S., Ronald G., Mathur R. et al. Pancreatic Steatosis and Its Relationship to b-Cell Dysfunction in Humans // Diabet. Care. – 2012; 35 (11): 2377–83.
  62. Pham Y., Bingham B., Bell C. et al. Prevalence of Pancreatic Steatosis at a Pediatric Tertiary Care Center // Southern Med. J. – 2016; 109: 196–8.
  63. Staaf J., Labmayr V., Paulmichl K. et al. Pancreatic Fat Is Associated With Metabolic Syndrome and Visceral Fat but Not Beta-Cell Function or Body Mass Index in Pediatric Obesity // Pancreas. – 2017; 46 (3): 358–65.
  64. Wu W.-C., Wang C.-Y. Association between non-alcoholic fatty pancreatic disease (nafpd) and the metabolic syndrome: case–control retrospective study // CardioVasc. Diabetol. – 2013; 12: 77. DOI: 10.1186/1475-2840-12-77.
  65. Watanabe S., Hojo M., Nagahara A. Metabolic syndrome and gastrointestinal diseases // J. Gastroenterol. – 2007; 42 (4): 267–74.